Waseem Jerjes

Prof. Waseem Jerjes

Imperial College London, London, City of London, UK
orcid
Professor of Practice in Primary Care at the Faculty of Medi...

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2010 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
Waseem JerjesWaseem Jerjes
Waseem Jerjes
TUTahwinder Upile
Tahwinder Upile
APAviva Petrie
Aviva Petrie
ARAndrew Riskalla
Andrew Riskalla
ZHZaid Hamdoon
Zaid Hamdoon
CHColin Hopper
Colin Hopper
The incidence of oral squamous cell carcinoma remains high. Oral and oro-pharyngeal carcinomas are the sixth most common cancer in the world. Several clinicopathological parameters have been implicated in prognosis, recurrence and survival, following oral squamous cell carcinoma. In this retrospective analysis, clinicopathological parameters of 115 T1/T2 OSCC were studied and compared to recurrence and death from tumour-related causes.

14 October 2009 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
PGPeter Kc Goon
Peter Kc Goon
MSmargaret stanley
margaret stanley
JEJörg Ebmeyer
Jörg Ebmeyer
LSLars Steinsträsser
Lars Steinsträsser
TUTahwinder Upile
Tahwinder Upile
HSHolger Sudhoff
Holger Sudhoff
The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.

1 March 2010 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
Waseem JerjesWaseem Jerjes
Waseem Jerjes
TUTahwinder Upile
Tahwinder Upile
PSPriya Shah
Priya Shah
FNFarai Nhembe
Farai Nhembe
DGDipali Gudka
Dipali Gudka
CHColin Hopper
Colin Hopper

14 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Waseem JerjesWaseem Jerjes
Waseem Jerjes
Theodossis A. TheodossiouTheodossis A. Theodossiou
Theodossis A. Theodossiou
HHHenry Hirschberg
Henry Hirschberg
AHAnders Høgset
Anders Høgset
Anette WeyergangAnette Weyergang
Anette Weyergang
Kristian BergKristian Berg
Kristian Berg
Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activation, lead to rupture of the endocytic vesicles and the release of the macromolecules into the cytoplasmic matrix. This technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins (RIPs), gene-encoding plasmids, adenovirus and oligonucleotides and certain chemotherapeutics, such as bleomycin. This new intervention has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination. PCI is currently being evaluated in clinical trials. Data from the first-in-human phase I clinical trial as well as an update on the development of the PCI technology towards clinical practice is presented here.

1 October 2006 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
Waseem JerjesWaseem Jerjes
Waseem Jerjes
BSB. Swinson
B. Swinson
DMD.R. Moles
D.R. Moles
MEM. El-Maaytah
M. El-Maaytah
BBB. Banu
B. Banu
CHC. Hopper
C. Hopper

15 March 2011 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
Waseem JerjesWaseem Jerjes
Waseem Jerjes
TUTahwinder Upile
Tahwinder Upile
ZHZaid Hamdoon
Zaid Hamdoon
CMCharles Alexander Mosse
Charles Alexander Mosse
SASarah Akram
Sarah Akram
CHColin Hopper
Colin Hopper